1.87
price down icon3.11%   -0.06
after-market Handel nachbörslich: 1.87
loading
Schlusskurs vom Vortag:
$1.93
Offen:
$1.84
24-Stunden-Volumen:
42,105
Relative Volume:
0.66
Marktkapitalisierung:
$88.09M
Einnahmen:
$18.11M
Nettoeinkommen (Verlust:
$-18.95M
KGV:
-4.2743
EPS:
-0.4375
Netto-Cashflow:
-
1W Leistung:
-1.58%
1M Leistung:
-1.58%
6M Leistung:
+3.89%
1J Leistung:
-28.90%
1-Tages-Spanne:
Value
$1.84
$1.96
1-Wochen-Bereich:
Value
$1.60
$1.9999
52-Wochen-Spanne:
Value
$1.325
$3.5807

Adagene Inc Adr Stock (ADAG) Company Profile

Name
Firmenname
Adagene Inc Adr
Name
Telefon
-
Name
Adresse
-
Name
Mitarbeiter
138
Name
Twitter
Name
Nächster Verdiensttermin
2024-03-28
Name
Neueste SEC-Einreichungen
Name
ADAG's Discussions on Twitter

Vergleichen Sie ADAG mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
ADAG
Adagene Inc Adr
1.87 89.51M 18.11M -18.95M 0 -0.4375
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
470.13 119.21B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
560.93 59.16B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
325.28 40.57B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
571.23 34.02B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
295.59 29.19B 3.81B -644.79M -669.77M -6.24

Adagene Inc Adr Stock (ADAG) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-01-31 Herabstufung Morgan Stanley Overweight → Equal-Weight
2021-06-25 Eingeleitet China Renaissance Buy
2021-03-08 Eingeleitet Goldman Buy
2021-03-08 Eingeleitet Jefferies Buy
2021-03-08 Eingeleitet Morgan Stanley Overweight

Adagene Inc Adr Aktie (ADAG) Neueste Nachrichten

pulisher
Jul 16, 2025

Adagene Receives FDA Approval for Phase 2 Trial of Muzastotug in MSS CRC - AInvest

Jul 16, 2025
pulisher
Jul 16, 2025

Adagene Announces Regulatory Update on Clinical Development - GlobeNewswire

Jul 16, 2025
pulisher
Jul 16, 2025

Adagene (NASDAQ:ADAG) Trading Up 3.8% – Should You Buy? - Defense World

Jul 16, 2025
pulisher
Jul 15, 2025

Adagene Receives FDA Guidance On Future Clinical Development Of Experimental Cancer Drug: Retail Turns Optimistic By Stocktwits - Investing.com India

Jul 15, 2025
pulisher
Jul 15, 2025

Adagene advances muzastotug to phase 2 trial after FDA meeting By Investing.com - Investing.com South Africa

Jul 15, 2025
pulisher
Jul 15, 2025

Adagene Announces Regulatory Update on Clinical Development Plan for Muzastotug in Microsatellite Stable Colorectal Cancer Following Productive Type B Meeting with FDA - MarketScreener

Jul 15, 2025
pulisher
Jul 15, 2025

Adagene advances muzastotug to phase 2 trial after FDA meeting - Investing.com India

Jul 15, 2025
pulisher
Jul 15, 2025

Adagene Advances Clinical Plan for ADG126 in Colorectal Cancer After FDA Meeting - TipRanks

Jul 15, 2025
pulisher
Jul 15, 2025

Adagene Announces Regulatory Update on Clinical Development Plan for Muzastotug in Microsatellite Stable Colorectal Cancer Following Productive Type B (End of Phase 1) Meeting with FDA - GlobeNewswire

Jul 15, 2025
pulisher
Jul 15, 2025

Adagene's Cancer Drug Shows Breakthrough 29% Response Rate, FDA Fast-Tracks Phase 2 Trial - Stock Titan

Jul 15, 2025
pulisher
Jul 10, 2025

Adagene Inc. and ConjugateBio Inc. Partner to Develop Novel Antibody Drug Conjugate - MarketScreener

Jul 10, 2025
pulisher
Jul 09, 2025

Adagene to provide antibody to ConjugateBio for bispecific ADC development By Investing.com - Investing.com South Africa

Jul 09, 2025
pulisher
Jul 08, 2025

Adagene Partners With ConjugateBio to Develop ADC Programs - MarketScreener

Jul 08, 2025
pulisher
Jul 08, 2025

Adagene and ConjugateBio Partner to Develop Novel Antibody Drug Conjugate - GlobeNewswire

Jul 08, 2025
pulisher
Jul 08, 2025

Adagene to provide antibody to ConjugateBio for bispecific ADC development - Investing.com

Jul 08, 2025
pulisher
Jul 08, 2025

Adagene Enters $30B ADC Market Through Strategic ConjugateBio Partnership for Novel Cancer Therapeutics - Stock Titan

Jul 08, 2025
pulisher
Jul 01, 2025

Adagene announces up to $25 million strategic investment from Sanofi - GlobeNewswire

Jul 01, 2025
pulisher
Jul 01, 2025

Adagene stock jumps after Sanofi’s $25 million strategic investment By Investing.com - Investing.com India

Jul 01, 2025
pulisher
Jun 24, 2025

Adagene (NASDAQ:ADAG) Trading 0.3% Higher – Here’s Why - Defense World

Jun 24, 2025
pulisher
Jun 14, 2025

Adagene to present new ADG126 clinical data at ASCO-GI - MSN

Jun 14, 2025
pulisher
Jun 03, 2025

Is McKesson (MCK) Outperforming Other Medical Stocks This Year? - Yahoo Finance

Jun 03, 2025
pulisher
Jun 02, 2025

Adagene Announces Participation At Leerink’s Global Healthcare Conference 2025 - Bernama

Jun 02, 2025
pulisher
May 31, 2025

Adagene Inc. (NASDAQ:ADAG) Sees Significant Growth in Short Interest - Defense World

May 31, 2025
pulisher
May 27, 2025

Adagene to Present at Jefferies Global Healthcare Conference 2025 - The Manila Times

May 27, 2025
pulisher
May 27, 2025

Adagene Inc. to Participate in Jefferies Global Healthcare Conference 2025 with Fireside Chat and Investor Meetings - Nasdaq

May 27, 2025
pulisher
May 27, 2025

Exclusive: Adagene Leadership Reveals Latest Antibody Therapeutic Strategy at Major Jefferies Conference - Stock Titan

May 27, 2025
pulisher
May 23, 2025

Adagene (NASDAQ:ADAG) Trading Down 2.1% – Here’s Why - Defense World

May 23, 2025
pulisher
May 22, 2025

Adagene Reports Promising ADG126 Study Results at ASCO - TipRanks

May 22, 2025
pulisher
May 22, 2025

Adagene Announces Updated Data from Phase 1b/2 Study of - GlobeNewswire

May 22, 2025
pulisher
May 22, 2025

New Clinical Data: Adagene's ADG126 Achieves Breakthrough 29% Response Rate in Hard-to-Treat Colorectal Cancer - Stock Titan

May 22, 2025
pulisher
May 13, 2025

ADAGAdagene Inc. Latest Stock News & Market Updates - Stock Titan

May 13, 2025
pulisher
Apr 30, 2025

Adagene Inc. (NASDAQ:ADAG) Short Interest Update - Defense World

Apr 30, 2025
pulisher
Apr 28, 2025

Adagene Appoints John Maraganore, Ph.D. as Executive Advisor - GlobeNewswire

Apr 28, 2025
pulisher
Apr 28, 2025

Biotech Pioneer Behind $25B Alnylam Success Story Takes Strategic Role at Adagene's Cancer Drug Mission - Stock Titan

Apr 28, 2025
pulisher
Apr 23, 2025

Adagene Announces Upcoming Poster Presentation on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at American Society of Clinical Oncology (ASCO) Annual Meeting - The Manila Times

Apr 23, 2025
pulisher
Apr 23, 2025

Adagene Inc. Announces Poster Presentation on ADG126 at ASCO 2025 Conference - Nasdaq

Apr 23, 2025
pulisher
Apr 23, 2025

Adagene Announces Upcoming Poster Presentation on Masked - GlobeNewswire

Apr 23, 2025
pulisher
Apr 07, 2025

Adagene to Present at Stifel's 2025 Virtual Targeted Oncology Forum - The Manila Times

Apr 07, 2025
pulisher
Apr 07, 2025

Adagene to Present at Stifel’s 2025 Virtual Targeted Oncology Forum - GlobeNewswire

Apr 07, 2025
pulisher
Apr 07, 2025

Adagene Reveals New Oncology Strategy: CEO Set for Major Investor Presentation - Stock Titan

Apr 07, 2025
pulisher
Apr 07, 2025

FY2025 Earnings Estimate for Adagene Issued By HC Wainwright - Defense World

Apr 07, 2025
pulisher
Apr 05, 2025

Adagene (NASDAQ:ADAG) Earns “Buy” Rating from HC Wainwright - Defense World

Apr 05, 2025
pulisher
Mar 27, 2025

Adagene stock hits 52-week low at $1.62 amid market challenges By Investing.com - Investing.com South Africa

Mar 27, 2025
pulisher
Mar 27, 2025

Adagene stock hits 52-week low at $1.62 amid market challenges - Investing.com

Mar 27, 2025
pulisher
Mar 25, 2025

Adagene (ADAG) to Release Quarterly Earnings on Thursday - Defense World

Mar 25, 2025
pulisher
Mar 24, 2025

Adagene Reports 33% Overall Response Rate in Phase 2 Expansion of Muzastotug for MSS CRC, Highlights Financial Position and Future Milestones - Nasdaq

Mar 24, 2025
pulisher
Mar 24, 2025

Adagene Reports Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewswire

Mar 24, 2025
pulisher
Mar 24, 2025

Adagene Reveals Breakthrough Cancer Trial Results in 2024 Financial Update - Stock Titan

Mar 24, 2025
pulisher
Mar 14, 2025

Adagene Inc. (NASDAQ:ADAG) Short Interest Down 55.9% in February - Defense World

Mar 14, 2025
pulisher
Mar 13, 2025

Adagene to Present at 11th Annual Immuno-Oncology 360⁰ Summit - GlobeNewswire

Mar 13, 2025
pulisher
Mar 13, 2025

Adagene Inc. to Present ADG126 SAFEbody® Data at 11th Annual Immuno-Oncology 360⁰ Summit in Boston - Nasdaq

Mar 13, 2025

Finanzdaten der Adagene Inc Adr-Aktie (ADAG)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$21.80
price up icon 0.51%
$36.10
price up icon 1.26%
$102.92
price up icon 0.14%
$26.54
price up icon 0.76%
$111.44
price up icon 2.32%
biotechnology ONC
$295.59
price up icon 1.25%
Kapitalisierung:     |  Volumen (24h):